Granted Patent
B2
US 12,735,721 · App. 17/442,894 · Granted Sep 15, 2026
Engineered adeno-associated (AAV) vectors for transgene expression
Inventors:
Casey A. Maguire (Arlington, MA); Eloise Marie Hudry (Roxbury Crossing, MA); Killian S. Hanlon (Boston, MA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Engineered AAV vectors for transgene expression, e.g., in the CNS, PNS, inner ear, heart, or retina, and methods of use thereof. Also provided are methods for discovering new engineered AAV vectors that mediate transgene expression in desired cell types.
Claims (2)
1 . An adeno-associated vector (AAV) capsid protein comprising an amino acid sequence that comprises at least five contiguous amino acids from STTLYSP (SEQ ID NO: 1) or FVVGQSY (SEQ ID NO:2), wherein the contiguous amino acids are inserted between residues 588 and 589 of SEQ ID NO: 6.
2 . The AAV capsid protein of claim 1 , comprising an amino acid sequence that comprises at least six contiguous amino acids from STTLYSP (SEQ ID NO: 1) or FVVGQSY (SEQ ID NO: 2).
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 16, 2022
From: HANLON, KILLIAN S.
To: THE GENERAL HOSPITAL CORPORATION; PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 060225/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 28, 2022
From: MAGUIRE, CASEY A.; HUDRY, ELOISE MARIE
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 059416/0637 →
Continuity (2)
Provisional Application
62825703
· Mar 28, 2019
References Cited (358)
US 5399363A
· Liversidge et al.
· 1995
[cited by applicant]
US 5478745A
· Samulski et al.
· 1995
[cited by applicant]
US 5543158A
· Gref et al.
· 1996
[cited by applicant]
US 5552157A
· Yagi et al.
· 1996
[cited by applicant]
US 5565213A
· Nakamori et al.
· 1996
[cited by applicant]
US 5567434A
· Szoka, Jr.
· 1996
[cited by applicant]
US 5641515A
· Ramtoola
· 1997
[cited by applicant]
US 5738868A
· Shinkarenko
· 1998
[cited by applicant]
US 5741516A
· Webb et al.
· 1998
[cited by applicant]
US 5795587A
· Gao et al.
· 1998
[cited by applicant]
US 6001650A
· Colosi
· 1999
[cited by applicant]
US 6156303A
· Russell et al.
· 2000
[cited by applicant]
US 7198951B2
· Gao et al.
· 2007
[cited by applicant]
US 7504490B1
· Weinstock
· 2009
[cited by examiner]
US 9102949B2
· Gao et al.
· 2015
[cited by applicant]
US 9585971B2
· Deverman et al.
· 2017
[cited by applicant]
US 9920317B2
· Lee et al.
· 2018
[cited by applicant]
US 20030138772A1
· Gao et al.
· 2003
[cited by applicant]
US 20030194721A1
· Mikita et al.
· 2003
[cited by applicant]
US 20040214272A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20080311627A1
· Tetzner et al.
· 2008
[cited by applicant]
US 20090270480A1
· Amegadzie et al.
· 2009
[cited by applicant]
US 20180187213A1
· High et al.
· 2018
[cited by applicant]
CN 101883859
· 2010
[cited by applicant]
CN 109207520
· 2019
[cited by applicant]
JP 2008263851
· 2008
[cited by applicant]
RU 2611202
· 2017
[cited by applicant]
RU 2018128780
· 2018
[cited by applicant]
WO WO1998000041
· 1998
[cited by applicant]
WO WO1998010088
· 1998
[cited by applicant]
WO WO2003097685
· 2003
[cited by applicant]
WO WO2004112727A2
· 2004
[cited by applicant]
WO WO2006119432
· 2006
[cited by applicant]
WO WO2011119484A1
· 2011
[cited by applicant]
WO WO2015013148
· 2015
[cited by applicant]
WO WO2015038958
· 2015
[cited by applicant]
WO WO2015130840
· 2015
[cited by applicant]
WO WO2016134375A1
· 2016
[cited by applicant]
WO WO2017100791
· 2017
[cited by applicant]
WO WO2017136536
· 2017
[cited by applicant]
WO WO2018022608
· 2018
[cited by applicant]
WO WO2018022608A2
· 2018
[cited by examiner]
WO WO2018189244
· 2018
[cited by applicant]
WO WO2019028306
· 2019
[cited by applicant]
WO WO2019046069
· 2019
[cited by applicant]
WO WO2019169132A1
· 2019
[cited by examiner]
WO WO2019200016
· 2019
[cited by applicant]
WO WO2020014471
· 2020
[cited by applicant]
WO WO2020028751A2
· 2020
[cited by applicant]
WO WO2020077295
· 2020
[cited by applicant]
WO WO2020097372
· 2020
[cited by applicant]
WO WO2020160337A1
· 2020
[cited by applicant]
WO WO2020198737
· 2020
[cited by applicant]
WO WO2020210655A1
· 2020
[cited by applicant]
WO WO2021067448
· 2021
[cited by applicant]
WO WO2022232327
· 2022
[cited by applicant]
Office Action in Japanese Appln. No. 2021-557657, dated Mar. 5, 2024, 14 pages (with English translation).
[cited by applicant]
GenBank Accession No. KAA0147029.1, “hypothetical protein FNF29_07656 [Cafeteria roenbergensis],” dated Sep. 9, 2019, 2 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2022/026608, mailed on Oct. 12, 2022, 13 pages.
[cited by applicant]
Abelson et al., Methods in Enzymology, 2004, Academic Press, Eds., 971 pages.
[cited by applicant]
Ahmad et al., “Mutations of the protocadherin gene PCDH15 cause Usher syndrome type IF,” Am J Hum Genet., Jul. 2001, 69(1):25-34.
[cited by applicant]
Ahmad et al., “PCDH15 is expressed in the neurosensory epithelium of the eye and ear and mutant alleles are responsible for both USHIF and DFNB23,” Hum Mol Genet., Dec. 2003, 12(24):3215-23.
[cited by applicant]
Ahmad et al., “Restoration of connexin26 protein level in the cochlea completely rescues hearing in a mouse model of human connexin30-linked deafness,” Proc Natl Acad Sci U S A, Jan. 2007, 104(4):1337-41.
[cited by applicant]
Akil et al., “Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy,” Neuron, Jul. 2012, 75(2):283-93.
[cited by applicant]
Alagramam et al., “Mutations in protocadherin 15 and cadherin 23 affect tip links and mechanotransduction in mammalian sensory hair cells,” PLoS One, Apr. 2011, 6(4):e19183, 16 pages.
[cited by applicant]
Al-Moyed et al., “A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice, ” EMBO Mol Med., Jan. 2019, 11(1):e9396, 13 pages.
[cited by applicant]
Angueyra et al., “Leveraging Zebrafish to Study Retinal Degeneration,” Front Cell Dev Biol., Sep. 2018, 6:110, 19 pages.
[cited by applicant]
Araya-Secchi et al., “An elastic element in the protocadherin-15 tip link of the inner ear,” Nat Commun., Nov. 2016, 7:13458, 14 pages.
[cited by applicant]
Assad et al., “An active motor model for adaptation by vertebrate hair cells,” J Neurosci., Sep. 1992, 12(9):3291-309.
[cited by applicant]
Assad et al., “Tip-link integrity and mechanical transduction in vertebrate hair cells,” Neuron, Dec. 1991, 7(6):985-94.
[cited by applicant]
Azaiez et al., “Genomic Landscape and Mutational Signatures of Deafness-Associated Genes,” Am J Hum Genet., Oct. 2018, 103(4):484-497.
[cited by applicant]
Azaiez et al., “GJB2: the spectrum of deafness-causing allele variants and their phenotype,” Hum Mutat., Oct. 2004, 24(4):305-11.
[cited by applicant]
Ben-Yosef et al., “A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome,” N Engl J Med., Apr. 2003, 348(17):1664-70.
[cited by applicant]
Boshart et al., “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,” Cell, Jun. 1985, 41(2):521-30.
[cited by applicant]
Boulay et al., “Hearing is normal without connexin30,” J Neurosci., Jan. 2013, 33(2):430-4.
[cited by applicant]
Brownstein et al., “The R245X mutation of PCDH15 in Ashkenazi Jewish children diagnosed with nonsyndromic hearing loss foreshadows retinitis pigmentosa,” Pediatr Res., Jun. 2004, 55(6): 995-1000.
[cited by applicant]
Buenrostro et al., “Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position,” Nat Methods, Dec. 2013, 10(12):1213-8.
[cited by applicant]
Chamberlain et al., “Progress toward Gene Therapy for Duchenne Muscular Dystrophy,” Mol Ther., 2017, 25:1125-31.
[cited by applicant]
Chan et al., “Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems,” HHS Public Access Author Manuscript, published online Dec. 26, 2017; published in final edited form a…
[cited by applicant]
Chang et al., “Functional studies reveal new mechanisms for deafness caused by connexin mutations,” Otol Neurotol., Feb. 2009, 30(2):237-40.
[cited by applicant]
Chang et al., “Gap junction mediated intercellular metabolite transfer in the cochlea is compromised in connexin30 null mice,” PloS one, 2008, 3(12):e4088, 10 pages.
[cited by applicant]
Chang et al., “Timed conditional null of connexin26 in mice reveals temporary requirements of connexin26 in key cochlear developmental events before the onset of hearing,” Neurobiol Dis., Jan. 2015, 73:418-27.
[cited by applicant]
Chen et al., “Characterization of a knock-in mouse model of the homozygous p. V37I variant in Gjb2,” Sci Rep., Sep. 2016, 6:33279, 7 pages.
[cited by applicant]
Chen et al., “Developmental abnormalities in supporting cell phalangeal processes and cytoskeleton in the Gjb2 knockdown mouse model,” Dis Model Mech., Feb. 2018, 11(2):dmm033019, 11 pages.
[cited by applicant]
Chen et al., “Down regulated connexin26 at different postnatal stage displayed different types of cellular degeneration and formation of organ of Corti,” Biochem Biophys Res Commun., Feb. 2014, 445(1):71-7.
[cited by applicant]
Cheung et al., “Ca
[cited by applicant]
Chow et al., “Inducible Cre Recombinase Activity in Mouse Cerebellar Granule Cell Precursors and Inner Ear Hair Cells,” Dev Dyn., Nov. 2006, 235(11):2991-8.
[cited by applicant]
Christensen et al., “TRP channels in mechanosensation: Direct or indirect activation?,” Nat Rev Neurosci., Jul. 2007, 8(7):510-21.
[cited by applicant]
Chu et al., “SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen,” Gene, Mar. 1981, 13(2):197-202.
[cited by applicant]
Cohen-Salmon et al., “Targeted ablation of connexin26 in the inner ear epithelial gap junction network causes hearing impairment and cell death,” Curr Biol., Jul. 2002, 12(13):1106-11.
[cited by applicant]
Corey et al., “Kinetics of the receptor current in bullfrog saccular hair cells,” J Neurosci., May 1983, 3(5):962-76.
[cited by applicant]
Corey et al., “TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells,” Nature, Dec. 2004, 432(7018):723-30.
[cited by applicant]
Creyghton et al., “Histone H3K27ac separates active from poised enhancers and predicts developmental state,” Proc Natl Acad Sci U S A, Dec. 2010, 107(50):21931-6.
[cited by applicant]
Crispino et al., “BAAV mediated GJB2 gene transfer restores gap junction coupling in cochlear organotypic cultures from deaf Cx26Sox10Cre mice,” PloS one, 2011, 6(8):e23279, 11 pages.
[cited by applicant]
Crispino et al., “In vivo genetic manipulation of inner ear connexin expression by bovine adeno-associated viral vectors,” Sci Rep., Aug. 2017, 7(1):6567, 13 pages.
[cited by applicant]
Dai et al., “Rhesus Cochlear and Vestibular Functions Are Preserved After Inner Ear Injection of Saline Volume Sufficient for Gene Therapy Delivery,” J Assoc Res Otolaryngol., Aug. 2017, 18(4):601-617.
[cited by applicant]
Darcy et al., “Abstract 691: Dual adeno-associated viral Anc80 vector efficiently transduces inner ear cells in non-human primates,” Abstract, Presented at the 43rd Annual MidWinter Meeting, San Jose, CA, Jan. 25-29, 20…
[cited by applicant]
De Felipe et al., “Tricistronic and tetracistronic retroviral vectors for gene transfer,” Hum Gene Ther., Sep. 2000, 11(13):1921-31.
[cited by applicant]
De Felipe et al., “Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy,” Gene Ther., Feb. 1999, 6(2):198-208.
[cited by applicant]
Degen et al., “Connexin32 can restore hearing in connexin26 deficient mice,” Eur J Cell Biol., Oct. 2011, 90(10):817-24.
[cited by applicant]
del Castillo et al., “A novel deletion involving the connexin-30 gene, del(GJB6-d13s1854), found in trans with mutations in the GJB2 gene (connexin-26) in subjects with DFNB1 non-syndromic hearing impairment,” J Med Gen…
[cited by applicant]
del Castillo et al., “DFNB1 Non-syndromic Hearing Impairment: Diversity of Mutations and Associated Phenotypes,” Front Mol Neurosci., Dec. 2017, 10:428.
[cited by applicant]
Delmaghani et al., “Inner ear gene therapies take off: current promises and future challenges,” J Clin Med., Jul. 2020, 9(7):2309.
[cited by applicant]
Derby et al., “Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors,” Hear Res., Aug. 1999, 134(1-2):1-8.
[cited by applicant]
Dinculescu et al., “AAV-Mediated Clarin-1 Expression in the Mouse Retina: Implications for USH3A Gene Therapy,” PLOS One, Feb. 2016, 11(2):e0148874.
[cited by applicant]
Dinh et al., “Diverse deafness mechanisms of connexin mutations revealed by studies using in vitro approaches and mouse models,” Brain Res., Jun. 2009, 1277:52-69.
[cited by applicant]
Doane et al., “Regulatory elements in molecular networks,” Wiley Interdiscip Rev Syst Biol Med., May 2017, 9(3):10.1002/wsbm.1374, 13 pages.
[cited by applicant]
Doucette et al., “Profound, prelingual nonsyndromic deafness maps to chromosome 10q21 and is caused by a novel missense mutation in the Usher syndrome type IF gene PCDH15,” Eur J Hum Genet., May 2009, 17(5):554-64.
[cited by applicant]
Dulon et al., “Clarin-1 gene transfer rescues auditory synaptopathy in model of Usher syndrome,” J Clin Invest., Aug. 2018, 128(8):3382-3401.
[cited by applicant]
Dyka et al., “Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A,” Hum Gene Ther Methods, Apr. 2014, 25(2):166-77.
[cited by applicant]
Ellis et al., “A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype,” Virol …
[cited by applicant]
Extended European Search Report for Application No. EP 19785415.1, mailed Dec. 15, 2021, 11 pages.
[cited by applicant]
Feigenspan et al., “Expression of connexin36 in cone pedicles and OFF-cone bipolar cells of the mouse retina,” J Neurosci., Mar. 2004, 24(13):3325-34.
[cited by applicant]
Fetoni et al., “Cx26 partial loss causes accelerated presbycusis by redox imbalance and dysregulation of Nfr2 pathway,” Redox Biol., Oct. 2018, 19:301-317.
[cited by applicant]
Fields et al., “Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations,” Am J Hum Genet., Sep. 2002, 71(3):607-17.
[cited by applicant]
Fisher et al., “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis,” J Virol., Jan. 1996, 70(1):520-32.
[cited by applicant]
Forge et al., “Gap junctions and connexin expression in the inner ear,” Novartis Found Symp., 1999, 219:134-50.
[cited by applicant]
Forge et al., “Gap junctions in the inner ear: comparison of distribution patterns in different vertebrates and assessment of connexin composition in mammals,” J Comp Neurol., Dec. 2003, 467(2):207-31.
[cited by applicant]
Furler et al., “Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons,” Gene Ther., Jun. 2001, 8(…
[cited by applicant]
Garcia et al., “Localization of myosin-Iβ near both ends of tip links in frog saccular hair cells,” J Neurosci., Nov. 1998, 18(21):8637-47.
[cited by applicant]
Gaudelli et al., “Programmable base editing of A⋅T to G⋅C in genomic DNA without DNA cleavage,” Nature, Nov. 2017, 551(7681):464-471.
[cited by applicant]
Ge et al., “Structure of mouse protocadherin 15 of the stereocilia tip link in complex with LHFPL5,” eLife, Aug. 2018, 7:e38770, 24 pages.
[cited by applicant]
GenBank Accession No. AAM88774.1., “clarin-1 [
[cited by applicant]
Genbank Accession No. NM_004004.6., “
[cited by applicant]
Genbank Accession No. NP_001182723.1, “clarin-1 isoform d [
[cited by applicant]
Genbank Accession No. NP_001243748.1, clarin-1 isoform e [
[cited by applicant]
Genbank Accession No. NP_443721.1, clarin-1 isoform c [
[cited by applicant]
Genbank Accession No. NP_700433.1, clarin-1 isoform 1 [Mus musculus], dated Oct. 7, 2020, 3 pages.
[cited by applicant]
Genbank Accession No. NP_700434.1, “clarin-1 isoform 2 [Mus musculus],” dated Oct. 9, 2020, 4 pages.
[cited by applicant]
Genbank Accession No. NP_700435.1, “clarin-1 isoform 3 [Mus musculus],” dated Oct. 10, 2020, 3 pages.
[cited by applicant]
Genbank Accession No. NP_777367.1, “clarin-1 isoform a [Homo sapiens],” dated Dec. 14, 2020, 3 pages.
[cited by applicant]
Geng et al., “Modeling and Preventing Progressive Hearing Loss in Usher Syndrome III,” Sci Rep., Oct. 2017, 7(1):13480, 15 pages.
[cited by applicant]
Gossen et al., “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters,” Proc Natl Acad Sci U S A, Jun. 1992, 89(12):5547-51.
[cited by applicant]
Gossen et al., “Transcriptional activation by tetracyclines in mammalian cells,” Science, Jun. 1995, 268(5218):1766-9.
[cited by applicant]
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA,” Virology, Apr. 1973, 52(2):456-67.
[cited by applicant]
Gregorevic et al., “rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice,” Nat Med., Jul. 2006, 12(7):787-9.
[cited by applicant]
Grimm et al., “In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses,” J Virol., Jun. 2008, 82(12):5887-911.
[cited by applicant]
György et al., “Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss,” Nat Med., Jul. 2019, 25(7):1123-1130.
[cited by applicant]
György et al., “An AAV9 capsid variant efficiently transduces inner ear hair cells in mice and non-human primates and rescues hearing in a mouse model of human deafness,” Mol Ther Methods Clin Dev., Nov. 2018, 13:1-13.
[cited by applicant]
György et al., “Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV,” Mol Ther., Feb. 2017, 25(2):379-391.
[cited by applicant]
Halpin et al., “Self-processing 2A-polyproteins—a system for co-ordinate expression of multiple proteins in transgenic plants,” Plant J., Feb. 1999, 17(4):453-9.
[cited by applicant]
Hanlon et al., “151: AAV-S: A Novel AAV Vector Selected in Brain Transduces the Cochlea with High Efficiency,” Abstract, Presented at Proceedings of the 2020 American Society of Gene and Cell Therapy Annual Meeting, Vir…
[cited by applicant]
Hanlon et al., “AAV-S: A novel AAV vector selected in brain transduces the inner ear with high efficiency,” Poster, Presented at Proceedings of the ASGCT, Harvard Medical School, Boston, MA, Apr. 28, 2020, 1 page.
[cited by applicant]
Harvey et al., “Inducible control of gene expression: prospects for gene therapy,” Curr Opin Chem Biol., Aug. 1998, 2(4):512-8.
[cited by applicant]
Hasson et al., “Unconventional myosins in inner-ear sensory epithelia,” J Cell Biol., Jun. 1997, 137(6):1287-307.
[cited by applicant]
Hirsch et al., “Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors,” Methods Mol Biol., 2016, 1382:21-39.
[cited by applicant]
Holt et al., “A chemical-genetic strategy demonstrates myosin 1c mediates sensory adaptation in hair cells,” Cell, Feb. 2002, 108(3):371-81.
[cited by applicant]
Holt et al., “Functional expression of exogenous proteins in mammalian sensory hair cells infected with adenoviral vectors,” J Neurophysiol., Apr. 1999, 81(4):1881-8.
[cited by applicant]
Hrvatin et al., “Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex,” Nat Neurosci., Jan. 2018, 21(1):120-129.
[cited by applicant]
Huang et al., “Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts, ” Mol Cell Biol., 1995, 15(7):3864-3869.
[cited by applicant]
Iizuka et al., “Perinatal Gjb2 gene transfer rescues hearing in a mouse model of hereditary deafness,” Hum Mol Genet., Jul. 2015, 24(13):3651-61.
[cited by applicant]
Indzhykulian et al., “Molecular remodeling of tip links underlies mechanosensory regeneration in auditory hair cells,” PLoS Biol., 2013, 11(6):e1001583, 15 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/026852, mailed Oct. 22, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2021/050205, mailed Mar. 23, 2023, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/026852, mailed Jul. 10, 2019, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/050205, mailed Dec. 20, 2021, 16 pages.
[cited by applicant]
Iossa et al., “GJB2 Gene Mutations in Syndromic Skin Diseases with Sensorineural Hearing Loss,” Curr Genomics, Nov. 2011, 12(7):475-785.
[cited by applicant]
Isgrig et al., “AAV2.7m8 is a powerful viral vector for inner ear gene therapy,” Nat Commun., Jan. 2019, 10(1):427, 8 pages.
[cited by applicant]
Ivanchenko et al., “4: Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea,” Abstract, Presented at Proceedings of the 2020 American Society of Gene and Cell Therapy Annual Meetin…
[cited by applicant]
Ivanchenko et al., “AAV-S: A versatile capsid variant for transduction of mouse and primate inner ear,” Mol Ther Methods Clin Dev., Mar. 2021, 21:382-398.
[cited by applicant]
Ivanchenko et al., “Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea,” Hear Res., Sep. 2020, 394:107930, 11 pages.
[cited by applicant]
Johnson et al., “Connexin-Mediated Signaling in Nonsensory Cells Is Crucial for the Development of Sensory Inner Hair Cells in the Mouse Cochlea,” J Neurosci., Jan. 2017, 37(2):258-268.
[cited by applicant]
Jovičić et al., “Comprehensive Expression Analyses of Neural Cell-Type-Specific miRNAs Identify New Determinants of the Specification and Maintenance of Neuronal Phenotypes,” J Neurosci., Mar. 2013, 33(12):5127-37.
[cited by applicant]
Kamiya et al., “Assembly of the cochlear gap junction macromolecular complex requires connexin 26,” J Clin Invest., Apr. 2014, 124(4):1598-607.
[cited by applicant]
Kazmierczak et al., “Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory hair cells,” Nature, Sep. 2007, 449(7158):87-91.
[cited by applicant]
Kelsell et al., “Connexin 26 mutations in hereditary non-syndromic sensorineural deafness,” Nature, May 1997, 387(6628):80-3.
[cited by applicant]
Kenna et al., “Audiologic phenotype and progression in GJB2 (Connexin 26) hearing loss,” Arch Otolaryngol Head Neck Surg., Jan. 2010, 136(1):81-7.
[cited by applicant]
Keppeler et al., “Ultrafast optogenetic stimulation of the auditory pathway by targeting-optimized Chronos,” EMBO J, Dec. 2018, 37(24):e99649, 15 pages.
[cited by applicant]
Kiang et al., “Upstream genomic sequence of the human connexin26 gene,” Gene, Oct. 1997, 199(1-2):165-71.
[cited by applicant]
Kikuchi et al., “Gap junction systems in the mammalian cochlea,” Brain Res Brain Res Rev., Apr. 2000, 32(1):163-6.
[cited by applicant]
Kikuchi et al., “Gap junctions in the rat cochlea: immunohistochemical and ultrastructural analysis,” Anat Embryol (Berl)., Feb. 1995, 191(2):101-18.
[cited by applicant]
Klump et al., “Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy,” Gene Ther., May 2001, 8(10):811-7.
[cited by applicant]
Kodippili et al., “Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model,” Hum Gene Ther., Mar. 2018, 29(3):299-311.
[cited by applicant]
Koehler et al., “Generation of inner ear organoids containing functional hair cells from human pluripotent stem cells,” Nat Biotechnol., Jun. 2017, 35(6):583-589.
[cited by applicant]
Kohrman et al., “Gene therapy for deafness,” Gene Ther., Dec. 2013, 20(12):1119-23.
[cited by applicant]
Kwan et al., “TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction,” Neuron, Apr. 2006, 50(2):277-89.
[cited by applicant]
Landegger et al., “A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear,” Nat Biotechnol., Mar. 2017, 35(3):280-284.
[cited by applicant]
Lang et al., “Effects of chronic furosemide treatment and age on cell division in the adult gerbil inner ear,” J Assoc Res Otolaryngol., Jun. 2003, 4(2):164-75.
[cited by applicant]
Lee et al., “Efficient viral transduction in mouse inner ear hair cells with utricle injection and AAV9-PHP.B,” Hear Res., Sep. 2020, 394:107882, 11 pages.
[cited by applicant]
Lee et al., “Mice with conditional deletion of Cx26 exhibit no vestibular phenotype despite secondary loss of Cx30 in the vestibular end organs,” Hearing Res., Oct. 2015, 328:102-12.
[cited by applicant]
Levy et al., “Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses,” Nat Biomed Eng., Jan. 2020, 4(1):97-110.
[cited by applicant]
Li et al., “Characterization of slow-cycling cells in the mouse cochlear lateral wall,” PloS one, Jun. 2017, 12(6):e0179293.
[cited by applicant]
Li et al., “MicroRNAs in hair cell development and deafness,” Curr Opin Otolaryngol Head Neck Surg., Oct. 2010, 18(5):459-65.
[cited by applicant]
Li et al., “Notch inhibition induces mitotically generated hair cells in mammalian cochleae via activating the Wnt pathway,” Proc Natl Acad Sci U S A, Jan. 2015, 112(1):166-71.
[cited by applicant]
Lin et al., “Hearing loss and incident dementia,” Arch Neurol., Feb. 2011, 68(2):214-20.
[cited by applicant]
Lin et al., “Hearing loss prevalence in the United States,” Arch Intern Med., Nov. 2011, 171(20):1851-2.
[cited by applicant]
Lukashkina et al., “Amplification mode differs along the length of the mouse cochlea as revealed by connexin 26 deletion from specific gap junctions,” Sci Rep., Jul. 2017, 7(1):5185, 11 pages.
[cited by applicant]
Lustig et al., “Cochlear Gene Therapy,” Cold Spring Harb Perspect Med., Sep. 2019, 9(9):a033191, 15 pages.
[cited by applicant]
Ma et al., “Abstract 404: Connexin 26 in mature ears influences survival of hair cells and neurons,” Abstract, Presented at Proceedings of the 43rd Annual MidWinter Meeting, San Jose, CA, Jan. 25-29, 2020, 43:258-9, 3 p…
[cited by applicant]
Magari et al., “Pharmacologic control of a humanized gene therapy system implanted into nude mice,” J Clin Invest., Dec. 1997, 100(11):2865-72.
[cited by applicant]
Maguire et al., “Efficacy, Safety, and Durability of Voretigene Neparvovec-rzy1 in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials,” Ophthalmology, Sep. 2019, 126(9):1273-1285.
[cited by applicant]
Mahendrasingam et al., “Subcellular distribution and relative expression of fibrocyte markers in the CD/1 mouse cochlea assessed by semiquantitative immunogold electron microscopy,” J Histochem Cytochem., Nov. 2011, 59(…
[cited by applicant]
Mammano et al., “Inner Ear Connexin Channels: Roles in Development and Maintenance of Cochlear Function,” Cold Spring Harb Perspect Med., Jul. 2019, 9(7):a033233, 26 pages.
[cited by applicant]
Mason et al., “Universal infant hearing screening by automated auditory brainstem response measurement,” Pediatrics, Feb. 1998, 101(2):221-8.
[cited by applicant]
Matsuzaki et al., “Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain,” Neurosci Lett., Feb. 2018, 665:182-188.
[cited by applicant]
Mattion et al., “Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens,” J Virol., Nov. 1996, 70(11):8124-7.
[cited by applicant]
McCarthy, “Self-complementary AAV vectors; advances and applications,” Mol Ther., Oct. 2008, 16(10):1648-56.
[cited by applicant]
McLean et al., “GREAT improves functional interpretation of cis-regulatory regions,” Nat Biotechnol., May 2010, 28(5):495-501.
[cited by applicant]
Mei et al., “A deafness mechanism of digenic Cx26 (GJB2) and Cx30 (GJB6) mutations: Reduction of endocochlear potential by impairment of heterogeneous gap junctional function in the cochlear lateral wall,” Neurobiol Dis…
[cited by applicant]
Mutai et al., “Mitotic activity and specification of fibrocyte subtypes in the developing rat cochlear lateral wall,” Neuroscience, Nov. 2009, 163(4):1255-63.
[cited by applicant]
Narui et al., “Tuning Inner-Ear Tip-Link Affinity Through Alternatively Spliced Variants of Protocadherin-15,” Biochemistry, Mar. 2018, 57(11):1702-1710.
[cited by applicant]
Nickel et al., “Gap junctions and connexins in the inner ear: their roles in homeostasis and deafness,” Curr Opin Otolaryngol Head Neck Surg., Oct. 2008, 16(5):452-7.
[cited by applicant]
Niwa et al., “In vitro polyadenylation is stimulated by the presence of an upstream intron,” Genes Dev., Sep. 1990, 4(9):1552-9.
[cited by applicant]
No et al., “Ecdysone-inducible gene expression in mammalian cells and transgenic mice,” Proc Natl Acad Sci U S A, Apr. 1996, 93(8):3346-3351.
[cited by applicant]
Office Action in Chinese Appln. No. 202080038934.8, dated Aug. 26, 2023, 11 pages (with English translation).
[cited by applicant]
Office Action in Russian Appln. No. 2021131423, dated Aug. 8, 2023, 11 pages (with English translation).
[cited by applicant]
Office Action in Singapore Appln. No. 11202110165X, dated Aug. 16, 2023, 12 pages.
[cited by applicant]
Olson et al., “Post-translational tools expand the scope of synthetic biology,” Curr Opin Chem Biol., Aug. 2012, 16(3-4):300-6.
[cited by applicant]
Pan et al., “Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type lc,” Nat Biotechnol., Mar. 2017, 35(3):264-272.
[cited by applicant]
Pepermans et al., “The CD2 isoform of protocadherin-15 is an essential component of the tip-link complex in mature auditory hair cells,” EMBO Mol Med., Jul. 2014, 6(7):984-92.
[cited by applicant]
Powers et al., “A Partial Calcium-Free Linker Confers Flexibility to Inner-Ear Protocadherin-15,” Structure, Mar. 2017, 25(3):482-495.
[cited by applicant]
Rada-Iglesias et al., “A unique chromatin signature uncovers early developmental enhancers in humans,” Nature, Feb. 2011, 470(7333):279-83.
[cited by applicant]
Rees et al., “Base editing: precision chemistry on the genome and transcriptome of living cells,” Nat Rev Genet., Dec. 2018, 19(12):770-788.
[cited by applicant]
Rodriguez-Paris et al., “Comparative functional characterization of novel non-syndromic GJB2 gene variant p.Gly45Arg and lethal syndromic variant p.Gly45Glu,” PeerJ, Oct. 2016, 4:e2494, 18 pages.
[cited by applicant]
Ross, “Comments on the article “Persistent confusion of total entropy and chemical system entropy in chemical thermodynamics” [(1996) Proc. Natl. Acad. Sci. USA 93, 7452-7453],” Proc. Natl Acad Sci USA, Dec. 1996, 93(25…
[cited by applicant]
Ryan et al., “Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein,” EMBO J., Feb. 1994, 13(4):928-33.
[cited by applicant]
Sacheli et al., “Gene transfer in inner ear cells: a challenging race,” Gene Ther., Mar. 2013, 20(3):237-47.
[cited by applicant]
Scheffer et al., “Gene expression profiling identifies Hes6 as a transcriptional target of ATOH1 in cochlear hair cells, ” FEBS Lett., Oct. 2007, 581(24):4651-6.
[cited by applicant]
Scheffer et al., “The α1 subunit of nicotinic acetylcholine receptors in the inner ear: transcriptional regulation by ATOH1 and co-expression with the γ subunit in hair cells,” J Neurochem., Dec. 2007, 103(6):2651-64.
[cited by applicant]
Scheffer et al., “XIRP2, an actin-binding protein essential for inner ear hair-cell stereocilia,” Cell Rep., Mar. 2015, 10(11):1811-8.
[cited by applicant]
Senís et al., “CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox,” Biotechnol J., Nov. 2014, 9(11):1402-12.
[cited by applicant]
Shepherd et al., “The extent of adaptation in bullfrog saccular hair cells,” J Neurosci., Oct. 1994, 14(10):6217-29.
[cited by applicant]
Shu et al., “Identification of Adeno-Associated Viral Vectors That Target Neonatal and Adult Mammalian Inner Ear Cell Subtypes,” Hum Gene Ther., Sep. 2016, 27(9):687-99.
[cited by applicant]
Solc et al., “Molecular cloning of myosins from the bullfrog saccular macula: A candidate for the adaptation motor,” Auditory Neurosci., 1994, 1:63-75.
[cited by applicant]
Sotomayor et al., “In search of the hair-cell gating spring: Elastic properties of ankyrin and cadherin repeats,” Structure, Apr. 2005, 13(4):669-82.
[cited by applicant]
Sotomayor et al., “Structural determinants of cadherin-23 function in hearing and deafness,” Neuron, Apr. 2010, 66(1):85-100.
[cited by applicant]
Sotomayor et al., “Structure of a force-conveying cadherin bond essential for inner-ear mechanotransduction,” Nature, Dec. 2012, 492(7427):128-32.
[cited by applicant]
Srinivas et al., “Human diseases associated with connexin mutations,” Biochim Biophys Acta Biomembr., Jan. 2018, 1860(1):192-201.
[cited by applicant]
Sun et al., “Connexin30 null and conditional connexin26 null mice display distinct pattern and time course of cellular degeneration in the cochlea,” J Comp Neurol., Oct. 2009, 516(6):569-79.
[cited by applicant]
Suzuki et al., “Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction,” Sci Rep., Apr. 2017, 7:45524, 11 pages.
[cited by applicant]
Takada et al., “Connexin 26 null mice exhibit spiral ganglion degeneration that can be blocked by BDNF gene therapy,” Hearing Res., Mar. 2014, 309:124-35.
[cited by applicant]
Tao et al., “Delivery of adeno-associated virus vectors in adult mammalian inner-ear cell subtypes without auditory dysfunction,” Hum Gene Ther., Apr. 2018, 29(4):492-506.
[cited by applicant]
Trapani et al., “Effective delivery of large genes to the retina by dual AAV vectors,” EMBO Mol Med., Feb. 2014, 6(2):194-211.
[cited by applicant]
Trapani et al., “Seeing the Light after 25 Years of Retinal Gene Therapy,” Trends Mol Med., Aug. 2018, 24(8):669-681.
[cited by applicant]
Trapani, “Dual AAV Vectors for Stargardt Disease,” Methods Mol Biol., 2018, 1715:153-175.
[cited by applicant]
Truong et al., “Development of an intein-mediated split-Cas9 system for gene therapy,” Nucleic Acids Res., Jul. 2015, 43(13):6450-8.
[cited by applicant]
Tu et al., “Mapping and characterization of the basal promoter of the human connexin26 gene,” Biochim Biophys Acta., Nov. 1998, 1443(1-2):169-81.
[cited by applicant]
Västinsalo et al., “Alternative splice variants of the USH3A gene Clarin 1 (CLRN1),” Eur J Hum Genet., Jan. 2011, 19(1):30-5.
[cited by applicant]
Vogl et al., “Tryptophan-rich basic protein (WRB) mediates insertion of the tail-anchored protein otoferlin and is required for hair cell exocytosis and hearing,” EMBO J., Dec. 2016, 35(23):2536-2552.
[cited by applicant]
Wan et al., “Inner ear supporting cells: Rethinking the silent majority,” Semin Cell Dev Biol., May 2013, 24(5):448-59.
[cited by applicant]
Wang et al., “A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates,” Mol Ther Methods Clin Dev., Mar. 2018, 9:234-246.
[cited by applicant]
Wang et al., “Ligand-inducible and liver-specific target gene expression in transgenic mice,” Nat Biotechnol., Mar. 1997, 15(3):239-43.
[cited by applicant]
Wang et al., “Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator,” Gene Ther., May 1997, 4(5):432-41.
[cited by applicant]
Wang et al., “Targeted connexin26 ablation arrests postnatal development of the organ of Corti,” Biochem Biophys Res Commun., Jul. 2009, 385(1):33-7.
[cited by applicant]
Wassmer et al., “Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection,” Sci Rep., Mar. 2017, 7:45329, 10 pages.
[cited by applicant]
Watanabe et al., “Expression of the Sox10 gene during mouse inner ear development,” Brain Res Mol Brain Res., Dec. 2000, 84(1-2):141-5.
[cited by applicant]
Wilch et al., “A novel DFNB1 deletion allele supports the existence of a distant cis-regulatory region that controls GJB2 and GJB6 expression,” Clin Genet., Sep. 2010, 78(3):267-74.
[cited by applicant]
Wingard et al., “Cellular and Deafness Mechanisms Underlying Connexin Mutation-Induced Hearing Loss—A Common Hereditary Deafness,” Front Cell Neurosci., May 2015, 9:202, 13 pages.
[cited by applicant]
Wise et al., “The effect of deafness duration on neurotrophin gene therapy for spiral ganglion neuron protection,” Hearing Res., Aug. 2011, 278(1-2):69-76.
[cited by applicant]
Wright et al., “Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation,” Mol Ther., Jul. 2005, 12(1):171-8.
[cited by applicant]
Wu et al., “Hair-cell mechanotransduction persists in TRP channel knockout mice,” PloS One, May 2016, 11(5):e0155577, 22 pages.
[cited by applicant]
Xia et al., “Expression of connexin 26 and Na,K-ATPase in the developing mouse cochlear lateral wall: functional implications,” Brain Res., Oct. 1999, 846(1):106-11.
[cited by applicant]
Yang et al., “Gfi1-Cre knock-in mouse line: A tool for inner ear hair cell-specific gene deletion,” Genesis, Jun. 2010, 48(6):400-6.
[cited by applicant]
Yeh et al., “Abstract PS 172: In vivo base editing rescues hearing in a mouse model of recessive deafness,” Abstract, Presented at Proceedings of the 43rd Annual MidWinter Meeting, San Jose, CA, Jan. 25-29, 2020, 43:96-…
[cited by applicant]
Yeh et al., “In vivo base editing of post-mitotic sensory cells,” Nature Commun., Jun. 2018, 9(1):2184, 10 pages.
[cited by applicant]
Yu et al., “Supplementary Figure 2 to: Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice,” Gene Ther., Nov. 2013, 1 page.
[cited by applicant]
Yu et al., “Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice,” Gene Ther., Jan. 2014, 21(1):71-80.
[cited by applicant]
Zallocchi et al., “Localization and expression of clarin-1, the C1rn1 gene product, in auditory hair cells and photoreceptors,” Hear Res., Sep. 2009, 255(1-2):109-20.
[cited by applicant]
Zelante et al., “Connexin26 mutations associated with the most common form of non-syndromic neurosensory autosomal recessive deafness (DFNB1) in Mediterraneans,” Hum Mol Genet., Sep. 1997, 6(9):1605-9.
[cited by applicant]
Zhu et al., “Active cochlear amplification is dependent on supporting cell gap junctions,” Nature Commun., 2013, 4:1786, 8 pages.
[cited by applicant]
Partial European Search Report in European Appln. No. 20779113.8, dated Nov. 23, 2022, 12 pages.
[cited by applicant]
Extended European Search Report in European Appln. No. 20779113.8, dated Apr. 18, 2023, 13 pages.
[cited by applicant]
Akil et al., “Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model,” Proc. Natl. Acad. Sci. U S A, Mar. 2019, 116(10):4496-4501.
[cited by applicant]
Al-Zaidy et al., “VXS-101 (Onasemnogene Abeparvovec) for SMA 1 : Comparative Study with a Prospective Natural History Cohort,” J. Neuromuscul. Dis., 2019, 6(3):307-317.
[cited by applicant]
Aurnhammer et al., “Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences,” Hum Gene Ther Methods, Feb. 2012, 23(1):18-28.
[cited by applicant]
Berry and Asokan, “Cellular transduction mechanisms of adeno-associated viral vectors,” Curr Opin Virol, Dec. 2016, 21:54-60.
[cited by applicant]
Caron et al., “Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease,” Nucleic Acids Res., Jan. 2020, 48(1):36…
[cited by applicant]
Cehajic-Kapetanovic et al., “Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR,” Nat. Med., Mar. 2020, 26(3):354-359, 18 pages.
[cited by applicant]
Chen et al., “Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy,” Nat Med, Oct. 2009, 15(10):1215-1218.
[cited by applicant]
Christine et al., “Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease,” Ann. Neural., May 2019, 85(5):704-714.
[cited by applicant]
Dashkoff et al., “Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9,” Mol Ther Methods Clin Dev, 2016. 3:16081, 9 pages.
[cited by applicant]
D'Costa et al., “Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR,” Mol Ther Methods Clin Dev, 2016. 5:16019, 9 pages.
[cited by applicant]
Deverman et al., “Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain,” Nat Biotechnol, Feb. 2016, 34(2):204-9, 8 pages.
[cited by applicant]
Duan, “Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy” Mol. Ther., Oct. 2018, 26(10):2337-2356.
[cited by applicant]
Eichler et al., “Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy,” N. Engl. J. Med., Oct. 2017, 377(17):1630-1638, 9 pages.
[cited by applicant]
Gong et al., “Adenoassociated virus serotype 9-mediated gene therapy for X-linked adrenoleukodystrophy,” Mol. Ther., May 2015, 23(5):824-834.
[cited by applicant]
Gray and Samulski, “Vector design and considerations for CNS applications,” Gene Vector Design and Application to Treat Nervous System Disorders, 2011, 9 pages.
[cited by applicant]
Gray et al., “Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB),” Mol Ther, Mar. 2010, 18(3):570-8.
[cited by applicant]
Griciuc et al., “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta,” Neuron, May 2013, 78(4):631-43.
[cited by applicant]
György et al., “Gene Transfer with AAV9-PHP.B Rescues Hearing in a Mouse Model of Usher Syndrome 3A and Transduces Hair Cells in a Non-human Primate,” Mol Ther Methods Clin Dev, Jun. 2019, 13:1-13.
[cited by applicant]
Hanlon et al., “Selection of an Efficient AAV Vector for Robust CNS Transgene Expression,” Molecular Therapy: Methods and Clinical Development, Dec. 2019, 15:320-332.
[cited by applicant]
Hinderer et al., “Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN,” Hum Gene Ther, Mar. 2018, 29(3):285-298.
[cited by applicant]
Hordeaux et al., “The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier,” Mol Ther, May 2019, 27(5):912-921.
[cited by applicant]
Hordeaux et al., “The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice,” Mol Ther, Mar. 2018, 26(3):664-668.
[cited by applicant]
Hudry et al., “Exosome-associated AAV vector as a robust and convenient neuroscience tool,” Gene Ther, 2016, 23(4):380-92.
[cited by applicant]
Hughes et al., “AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease,” Hum. Mol. Genet., Sep. 2018, 27(17):3079-3098.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/025720, dated Oct. 7, 2021, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/025720, dated Jul. 27, 2020, 10 pages.
[cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee in International Appln. No. PCT/US2022/026608, mailed on Aug. 15, 2022, 2 pages.
[cited by applicant]
Isgrig et al., “Gene Therapy Restores Balance and Auditory Functions in a Mouse Model of Usher Syndrome,” Mol. Ther., Mar. 2017, 25(3):780-791.
[cited by applicant]
Keskin et al., “AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient- Derived Neuronal Cultures and Astrocytes,” Mol. Ther. Methods Clin. Dev., Dec. 2019, 15:275-284.
[cited by applicant]
Koerber et al., “Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles,” Nat Protoc, Jul. 2006, 1(2):701-6.
[cited by applicant]
Körbelin et al., “Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries,” Mol Ther, Jun. 2016, 24(6):1050-1061.
[cited by applicant]
Leone et al., “Long-term follow- up after gene therapy for canavan disease,” Sci. Transl. Med., 2012, 4(165):165ra163, 14 pages.
[cited by applicant]
Li and Samulski, “Engineering adeno-associated virus vectors for gene therapy,” Nature Reviews Genetics, Apr. 2020, 21(4):255-272, 18 pages.
[cited by applicant]
Lopes and Williams, “Gene therapy for the retinal degeneration of usher syndrome caused by mutations in MYO7A,” Cold Spring Harb. Perspect. Med., Jun. 2015, 5(6):a017319, 10 pages.
[cited by applicant]
Maguire et al., “Efficacy, Safety, and Durability of Voretigene Neparvovec-rzy1 in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials,” Ophthalmology, 2019, 126(9):1273-1285.
[cited by applicant]
Maguire et al., Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther, 2012, 20(5):960-71.
[cited by applicant]
Manno et al., “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response,” Nat Med, 2006, 12(3):342-7.
[cited by applicant]
Matsuzaki et al., “Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice, ” Mol Tuer, 2019, 27(4):700-704.
[cited by applicant]
Mendell et al., “Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy,” N Engl J Med, Nov. 2017, 377(18):1713-1722.
[cited by applicant]
Millington-Ward et al., “Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa,” Mol. Ther., Apr. 2011, 19(4):642-649.
[cited by applicant]
Mookherjee et al., “Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy,” Hum. Mol. Genet., Nov. 2015, 24(22):6446-58.
[cited by applicant]
Nathwani, “Gene therapy for hemophilia,” Hematol. Am Soc Hematol Educ Program, Dec. 2019, 2019(1):1-8.
[cited by applicant]
Nist-Lund et al., “Improved TMC1 gene therapy restores hearing and balance in mice with genetic inner ear disorders,” Nat. Commun., 2019, 10(1):236, 14 pages.
[cited by applicant]
Nonnenmacher et al., “High capsid-genome correlation facilitates creation of AAV libraries for directed evolution,” Mol Ther, Apr. 2015, 23(4):675-82.
[cited by applicant]
Park et al., “Generation of transgenic marmosets expressing genetically encoded calcium indicators,” Sci Rep, Oct. 2016, 6:34931, 12 pages.
[cited by applicant]
Paulk et al., “Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity,” Mol Ther, Jan. 2018, 26(1):289-303.
[cited by applicant]
Paulk et al., “Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle,” Mol Ther Methods Clin Dev, Jul. 2018, 10:144-155.
[cited by applicant]
Pulicherla et al., “Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer,” Mol Ther, Jun. 2011, 19(6):1070-1078.
[cited by applicant]
Remes et al., “AAV-mediated TIMP-1 overexpression in aortic tissue reduces the severity of allograft vasculopathy in mice,” J. Hear. Lung Transplant, Apr. 2020, 39(4):389-398, 10 pages.
[cited by applicant]
Sallach et al., “Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy,” Mol Ther, May 2014, 22(5):929-39.
[cited by applicant]
Sasaki et al., “Generation of transgenic non-human primates with germline transmission,” Nature, May 2009, 459(7246):523-7.
[cited by applicant]
Tan et al., “AAV-ie enables safe and efficient gene transfer to inner ear cells,” Nat. Commun., Aug. 2019, 10(1):3733, 10 pages.
[cited by applicant]
Tse et al., “Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion,” Proc Natl Acad Sci U S A, May 2017, 114(24):E4812-E4821.
[cited by applicant]
Wan et al., “Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy,” Sci. Rep., Feb. 2016, 6:21587, 10 pages.
[cited by applicant]
Watters et al., “Identification and dynamic regulation of tight junction protein expression in human neural stem cells,” Stem Cells Dev, Jun. 2015, 24(12):1377-89.
[cited by applicant]
Xu et al., “A combination of mutations enhances the neurotropism of AAV-2,” Virology, 2005, 341:203-214.
[cited by applicant]
Yang et al., “Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy,” EBioMedicine, Aug. 2016, 10:258-268.
[cited by applicant]
Yu et al., “Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice,” Nat. Commun., Mar. 2017, 8:14716, 15 pages.
[cited by applicant]
Zhang et al., “Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success,” Front. Mol. Neurosci., Jun. 2018, 11:221, 15 pages.
[cited by applicant]
Office Action in Japanese Appln. No. 2021-557657, dated Sep. 24, 2024, 6 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202080038934.8, dated Sep. 7, 2024, 9 pages (with English translation).
[cited by applicant]
Office Action in Russian Appln. No. 2021131423, mailed on Oct. 24, 2024, 6 pages (with English translation).
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2022/026608, mailed Nov. 9, 2023, 8 pages.
[cited by applicant]
Körbelin et al., “A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases,” EMBO Mol Med., Jun. 2016, 8(6):609-25.
[cited by applicant]
Lang et al., “Standard screening methods underreport AAV-mediated transduction and gene editing,” Nat Commun., Jul. 2019, 10(1):3415, 10 pages.
[cited by applicant]
Prabhakar et al., “AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice,” Exp Anim., Nov. 2021, 70(4):450-458.
[cited by applicant]
Ravindra Kumar et al., “Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types,” Nat Methods, May 2020, 17(5):541-550.
[cited by applicant]
Xie et al., “MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression,” Mol Ther., Mar. 2011, 19(3):526-35.
[cited by applicant]
Office Action in Russian Appln. No. 2021131423, dated Dec. 21, 2023, 12 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202080038934.8, dated Jun. 27, 2024, 11 pages (with English translation).
[cited by applicant]
Office Action in Australian Appln. No. 2020248116, mailed on Dec. 13, 2024, 6 pages.
[cited by applicant]
Office Action in Singaporean Appln. No. 11202110165X, mailed on Feb. 11, 2025, 3 pages.
[cited by applicant]
Notice of Allowance in Japanese Appln. No. 2021-557657, mailed on Feb. 18, 2025, 6 pages (with English translation).
[cited by applicant]
Notice of Allowance in Russian Appln. No. 2021131423, mailed on Mar. 3, 2025, 15 pages (with English translation).
[cited by applicant]
Office Action in Korean Appln. No. 10-2021-7034532, mailed on Feb. 7, 2025, 12 pages (with English translation).
[cited by applicant]
Naso et al., “Adeno-associated virus (AAV) as a vector for gene therapy,” BioDrugs, Aug. 2017, 31(4):317-34.
[cited by applicant]
Partial European Search Report in European Appln. No. 22796682.7, mailed on Apr. 30, 2025, 13 pages.
[cited by applicant]
GenBank Accession No. CDJ33539, “hypothetical protein EMH_0016460 [Eimeria mitis], ” Nov. 5, 2013, 1 page.
[cited by applicant]
Office Action in Canadian Appln. No. 3135292, mailed on Aug. 19, 2025, 8 pages.
[cited by applicant]
Extended European Search Report in European Appln. No. 22796682.7, mailed on Jul. 21, 2025, 11 pages.
[cited by applicant]
Notice of Allowance in Korean Appln. No. 10-2021-7034532, mailed on Dec. 3, 2025, 7 pages (with English translation).
[cited by applicant]
Office Action in Australian Appln. No. 2020248116, mailed on Sep. 29, 2025, 4 pages.
[cited by applicant]
Office Action in Israeli Patent Appln. No. 286725, mailed Dec. 16, 2025, 4 pages.
[cited by applicant]
Office Action in Mexican Patent Appln. No. MX/a/2021/011701, mailed Dec. 2, 2025, 17 pages (with English translation).
[cited by applicant]